Tanvex BioPharma Inc (TW:6541) — Market Cap & Net Worth
Market Cap & Net Worth: Tanvex BioPharma Inc (6541)
Tanvex BioPharma Inc (TW:6541) has a market capitalization of $257.13 Million (NT$8.16 Billion) as of September 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #15635 globally and #698 in its home market, demonstrating a -2.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tanvex BioPharma Inc's stock price NT$30.80 by its total outstanding shares 264986367 (264.99 Million). Also see Tanvex BioPharma Inc total assets for a full breakdown of the balance sheet.
Tanvex BioPharma Inc Market Cap History: 2015 to 2026
Tanvex BioPharma Inc's market capitalization history from 2015 to 2026. Data shows change from $1.82 Billion to $257.13 Million (-10.66% CAGR). Also see 6541 cash flow metrics for how efficiently the company converts equity into cash flow.
Tanvex BioPharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tanvex BioPharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Tanvex BioPharma Inc (6541) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.15x
Tanvex BioPharma Inc's market cap is 1.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $309.34 Million | $300.00K | -$2.10 Billion | 1031.14x | N/A |
| 2021 | $485.05 Million | $5.41 Million | -$1.54 Billion | 89.72x | N/A |
| 2022 | $293.03 Million | $22.40 Million | -$1.64 Billion | 13.08x | N/A |
| 2023 | $543.49 Million | $61.41 Million | -$2.14 Billion | 8.85x | N/A |
| 2024 | $544.32 Million | $34.68 Million | -$1.38 Billion | 15.70x | N/A |
| 2025 | $459.17 Million | $400.97 Million | -$1.50 Billion | 1.15x | N/A |
Competitor Companies of 6541 by Market Capitalization
Companies near Tanvex BioPharma Inc in the global market cap rankings as of September 18, 2026. Review Tanvex BioPharma Inc (6541) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tanvex BioPharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Tanvex BioPharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Tanvex BioPharma Inc's market cap moved from $1.82 Billion to $ 257.13 Million, with a yearly change of -10.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$257.13 Million | -44.00% |
| 2025 | NT$459.17 Million | -15.64% |
| 2024 | NT$544.32 Million | +0.15% |
| 2023 | NT$543.49 Million | +85.47% |
| 2022 | NT$293.03 Million | -39.59% |
| 2021 | NT$485.05 Million | +56.80% |
| 2020 | NT$309.34 Million | -14.70% |
| 2019 | NT$362.64 Million | -27.93% |
| 2018 | NT$503.17 Million | -16.68% |
| 2017 | NT$603.93 Million | -51.13% |
| 2016 | NT$1.24 Billion | -32.12% |
| 2015 | NT$1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Tanvex BioPharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $257.13 Million USD |
| MoneyControl | $257.13 Million USD |
| MarketWatch | $257.13 Million USD |
| marketcap.company | $257.13 Million USD |
| Reuters | $257.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicine… Read more